tetano
Editor, Senior Moderator
Curr Opin Ophthalmol
. 2020 Jul 27.
doi: 10.1097/ICU.0000000000000682. Online ahead of print.
Ophthalmic manifestations of coronavirus disease 2019 and ocular side effects of investigational pharmacologic agents
Daniel J Olson[SUP] 1 [/SUP], Arko Ghosh, Alice Yang Zhang
Affiliations
Abstract
Purpose of review: To compile and report the ocular manifestations of coronavirus disease 2019 (COVID-19) infection and summarize the ocular side effects of investigational treatments of this disease.
Recent findings: Conjunctivitis is by far the most common ocular manifestation of COVID-19 with viral particles being isolated from tears/secretions of infected individuals. Multiple therapeutic options are being explored across a variety of medication classes with diverse ocular side effects.
Summary: Eye care professionals must exercise caution, as conjunctivitis may be the presenting or sole finding of an active COVID-19 infection. While no currently studied therapeutic agents have been found to reliably treat COVID-19, early vaccination trials are progressing and show promise. A video abstract is available for a more detailed summary. VIDEO ABSTRACT: http://links.lww.com/COOP/A36.
. 2020 Jul 27.
doi: 10.1097/ICU.0000000000000682. Online ahead of print.
Ophthalmic manifestations of coronavirus disease 2019 and ocular side effects of investigational pharmacologic agents
Daniel J Olson[SUP] 1 [/SUP], Arko Ghosh, Alice Yang Zhang
Affiliations
- PMID: 32740062
- DOI: 10.1097/ICU.0000000000000682
Abstract
Purpose of review: To compile and report the ocular manifestations of coronavirus disease 2019 (COVID-19) infection and summarize the ocular side effects of investigational treatments of this disease.
Recent findings: Conjunctivitis is by far the most common ocular manifestation of COVID-19 with viral particles being isolated from tears/secretions of infected individuals. Multiple therapeutic options are being explored across a variety of medication classes with diverse ocular side effects.
Summary: Eye care professionals must exercise caution, as conjunctivitis may be the presenting or sole finding of an active COVID-19 infection. While no currently studied therapeutic agents have been found to reliably treat COVID-19, early vaccination trials are progressing and show promise. A video abstract is available for a more detailed summary. VIDEO ABSTRACT: http://links.lww.com/COOP/A36.